BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Science in Boston - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://scienceinboston.com
X-WR-CALDESC:Events for Science in Boston
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20180311T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20181104T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20190310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20191103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20200308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20201101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20210314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20211107T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191216T090000
DTEND;TZID=America/New_York:20191217T163000
DTSTAMP:20260716T173141
CREATED:20191125T161328Z
LAST-MODIFIED:20191125T161646Z
UID:7348-1576486800-1576600200@scienceinboston.com
SUMMARY:Biotech 101: The Science & Business of Biotech\, Dec 2019
DESCRIPTION:Overview\n\nNew to the life sciences industry? Do you need to have a better understanding of the science and business models driving the industry? Biotech 101: The Science of Biotech & The Business of Biotech provides a thorough overview of the industry at a reduced cost. The program covers two full days of biotechnology information for non-science professionals who may be working or looking to work in the biopharmaceutical industry. \nTarget Audience:\n\nNon-science professionals from all sectors of the biotech\, pharma\, and life sciences industries\, including: sales\, marketing\, HR\, legal\, manufacturing\, business development\, finance\, management\, government relations\, IT\, safety\, tech transfer offices\nPatient advocacy groups\, disease foundations\nPolicy makers\, lobbyists\, attorneys\nVenture capitalists\, angel investors\, banks\, analysts\, financial managers\nInsurance brokers\, real estate professionals\nConsultants\, public relations specialists\, journalists\nUniversity administrators\, research institute support staff\nEnvironmental & Health & Safety Engineers\n\nDay 1 \nWhat is the science behind biotechnology? Explore the key concepts on which the industry is built through hands-on activities and simple lab techniques. This program is designed to provide non-science professionals with a better understanding of the molecular biology that drives the production of most biopharmaceutical products and to help them better understand the research activities in their organizations. \nIn this course you will learn: How medicines made through biotechnology differ from other medicines\, what DNA does\, how the body makes proteins\, how genetic engineering works\, what personalized medicine is\, and how proteins are made in the lab.  Participants will perform agarose gel electrophoresis and protein purification. \nDay 2 \nThe Business of Biotech explores the business considerations that drive company strategies. Gain a deeper understanding of how companies are funded\, which government agencies regulate the sector and how different departments need to be aligned to be successful. This day provides an overview of how the industry works\, why it works the way it does\, and how the industry may change in the years ahead. For those considering careers in the biopharma space or transitioning from the science and technical aspects of the industry to the business side\, this course delivers a sound\, basic understanding of the “business of biotech”. \nCourse content includes: From Discovery to Commercialization\, Role of Non-profit Basic Research\, Intellectual Property Considerations & Funding Sources\, Organizational Characteristics\, and The Ecosystem and the Future of Biopharma \nInstructors:\nMichelle Mischke\, PhD is the Director of Biotechnology Education Programs at MassBioEd. She has extensive research\, teaching\, and administrative experience. She taught a range of undergraduate biology courses at MIT and was a course coordinator and content developer for 7.00x\, the first large online biology course offered by edX. While at MIT\, she was involved in K-12 science outreach and education programs. Michelle holds a B.A. in both Biology and Chemistry from Colorado State University and a Ph.D. in Pharmacology from the University of Medicine and Dentistry of New Jersey. Prior to joining the Department of Biology at MIT\, she worked as a postdoctoral fellow at Harvard University. \nImran Nasrullah\, MS\, JD\, CLP has twenty years of experience in biopharmaceutical business development\, licensing\, and economic development experience. Currently he serves as Director of Innovation Sourcing at Boehringer Ingelheim\, where he facilitates access to new scientific innovation emerging from the Boston area and forges business relationships within the Boston Cambridge life-science ecosystem. He served on the Senior Advisory Board for Cellanyx after heading strategic alliances and business development for T1D First\, a disease foundation dedicated to curing Type 1 Diabetes. As Head of Strategic Alliances\, he led industry\, academic and not-for-profit partnerships. Prior to T1D First\, Imran served as CBO at MassBio\, where he built MassBio’s business & investor and economic development outreach programs – known as MassBio Innovation Services – to help companies raise capital and identify strategic partnering and licensing opportunities. Up until then\, Imran worked for ten years in the biopharmaceutical industry as directors of business development and licensing for Genzyme Corporation\, Millennium Pharmaceuticals. Imran started his licensing career working for Mayo Clinic and then later\, the Dana Farber Cancer Institute. Imran is author to several publications regarding the impact of exercise on auto-immune disease patients. He received the 2010 Outstanding 50 Asian American Business awardee. Imran received his MS in Physiology at the University of Colorado and his BS in Exercise Physiology at the University of Massachusetts Amherst. He holds a JD in Intellectual Property and Licensing from Suffolk University Law School.
URL:https://scienceinboston.com/event/biotech-101-the-science-business-of-biotech-dec-2019/
LOCATION:MassBio\, 300 Technology Square 8th Fl\, Cambridge\, MA\, 02139\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191216T090000
DTEND;TZID=America/New_York:20191217T163000
DTSTAMP:20260716T173141
CREATED:20191125T161328Z
LAST-MODIFIED:20191125T161328Z
UID:27409-1576486800-1576600200@scienceinboston.com
SUMMARY:Biotech 101: The Science & Business of Biotech\, Dec 2019
DESCRIPTION:Overview\n\nNew to the life sciences industry? Do you need to have a better understanding of the science and business models driving the industry? Biotech 101: The Science of Biotech & The Business of Biotech provides a thorough overview of the industry at a reduced cost. The program covers two full days of biotechnology information for non-science professionals who may be working or looking to work in the biopharmaceutical industry. \nTarget Audience:\n\nNon-science professionals from all sectors of the biotech\, pharma\, and life sciences industries\, including: sales\, marketing\, HR\, legal\, manufacturing\, business development\, finance\, management\, government relations\, IT\, safety\, tech transfer offices\nPatient advocacy groups\, disease foundations\nPolicy makers\, lobbyists\, attorneys\nVenture capitalists\, angel investors\, banks\, analysts\, financial managers\nInsurance brokers\, real estate professionals\nConsultants\, public relations specialists\, journalists\nUniversity administrators\, research institute support staff\nEnvironmental & Health & Safety Engineers\n\nDay 1 \nWhat is the science behind biotechnology? Explore the key concepts on which the industry is built through hands-on activities and simple lab techniques. This program is designed to provide non-science professionals with a better understanding of the molecular biology that drives the production of most biopharmaceutical products and to help them better understand the research activities in their organizations. \nIn this course you will learn: How medicines made through biotechnology differ from other medicines\, what DNA does\, how the body makes proteins\, how genetic engineering works\, what personalized medicine is\, and how proteins are made in the lab.  Participants will perform agarose gel electrophoresis and protein purification. \nDay 2 \nThe Business of Biotech explores the business considerations that drive company strategies. Gain a deeper understanding of how companies are funded\, which government agencies regulate the sector and how different departments need to be aligned to be successful. This day provides an overview of how the industry works\, why it works the way it does\, and how the industry may change in the years ahead. For those considering careers in the biopharma space or transitioning from the science and technical aspects of the industry to the business side\, this course delivers a sound\, basic understanding of the “business of biotech”. \nCourse content includes: From Discovery to Commercialization\, Role of Non-profit Basic Research\, Intellectual Property Considerations & Funding Sources\, Organizational Characteristics\, and The Ecosystem and the Future of Biopharma \nInstructors:\nMichelle Mischke\, PhD is the Director of Biotechnology Education Programs at MassBioEd. She has extensive research\, teaching\, and administrative experience. She taught a range of undergraduate biology courses at MIT and was a course coordinator and content developer for 7.00x\, the first large online biology course offered by edX. While at MIT\, she was involved in K-12 science outreach and education programs. Michelle holds a B.A. in both Biology and Chemistry from Colorado State University and a Ph.D. in Pharmacology from the University of Medicine and Dentistry of New Jersey. Prior to joining the Department of Biology at MIT\, she worked as a postdoctoral fellow at Harvard University. \nImran Nasrullah\, MS\, JD\, CLP has twenty years of experience in biopharmaceutical business development\, licensing\, and economic development experience. Currently he serves as Director of Innovation Sourcing at Boehringer Ingelheim\, where he facilitates access to new scientific innovation emerging from the Boston area and forges business relationships within the Boston Cambridge life-science ecosystem. He served on the Senior Advisory Board for Cellanyx after heading strategic alliances and business development for T1D First\, a disease foundation dedicated to curing Type 1 Diabetes. As Head of Strategic Alliances\, he led industry\, academic and not-for-profit partnerships. Prior to T1D First\, Imran served as CBO at MassBio\, where he built MassBio’s business & investor and economic development outreach programs – known as MassBio Innovation Services – to help companies raise capital and identify strategic partnering and licensing opportunities. Up until then\, Imran worked for ten years in the biopharmaceutical industry as directors of business development and licensing for Genzyme Corporation\, Millennium Pharmaceuticals. Imran started his licensing career working for Mayo Clinic and then later\, the Dana Farber Cancer Institute. Imran is author to several publications regarding the impact of exercise on auto-immune disease patients. He received the 2010 Outstanding 50 Asian American Business awardee. Imran received his MS in Physiology at the University of Colorado and his BS in Exercise Physiology at the University of Massachusetts Amherst. He holds a JD in Intellectual Property and Licensing from Suffolk University Law School.
URL:https://scienceinboston.com/event/biotech-101-the-science-business-of-biotech-dec-2019-2/
LOCATION:MassBio\, 300 Technology Square 8th Fl\, Cambridge\, MA\, 02139\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191218T080000
DTEND;TZID=America/New_York:20191218T100000
DTSTAMP:20260716T173141
CREATED:20191125T161607Z
LAST-MODIFIED:20191125T161607Z
UID:7351-1576656000-1576663200@scienceinboston.com
SUMMARY:Fireside Chat with Stiris Research’s Experts on Health Authority Inspection
DESCRIPTION:Description\nHealth authority inspections evoke reactions that are situated somewhere on the spectrum between panic to preparedness. Between innovative studies\, collaborating with vendors\, and supporting your clinical trial sites\, there is a multitude of scenarios where you may find yourself questioning your inspection preparedness. Organizations want to know: where can things go wrong and how do we set ourselves up for the best results? \nStiris’ QA Expert\, Kara Lee McWatters\, and President & CEO\, Shantal Feltham\, will discuss common findings from health authority inspections\, how to avoid pitfalls during an inspection\, day-to-day strategies you can implement\, challenges\, successes\, and real-life anecdotes to help you be inspection ready. Following the fireside chat\, there will be an open Q&A forum\, where you’ll have the opportunity to dig deeper into the information provided or ask your own questions. \nWant to guarantee your inspection question gets addressed? Submit ALL your questions via email at Auditing@StirisResearch.com or on Twitter @StirisResearch. \nStiris Research is a MassBIO member. MassBio Forums are networking and professional development that is planned for members by members to discuss industry hot topics\, tackle common challenges and share best practices. For those who cannot make it to Cambridge\, MassBio also webcasts all presentations live and archives the videos for on-demand replay in the Knowledge Base. See massbio.org for more information
URL:https://scienceinboston.com/event/fireside-chat-with-stiris-researchs-experts-on-health-authority-inspection/
LOCATION:MassBio\, 300 Technology Square 8th Fl\, Cambridge\, MA\, 02139\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191218T080000
DTEND;TZID=America/New_York:20191218T100000
DTSTAMP:20260716T173141
CREATED:20191125T161607Z
LAST-MODIFIED:20191125T161607Z
UID:27410-1576656000-1576663200@scienceinboston.com
SUMMARY:Fireside Chat with Stiris Research’s Experts on Health Authority Inspection
DESCRIPTION:Description\nHealth authority inspections evoke reactions that are situated somewhere on the spectrum between panic to preparedness. Between innovative studies\, collaborating with vendors\, and supporting your clinical trial sites\, there is a multitude of scenarios where you may find yourself questioning your inspection preparedness. Organizations want to know: where can things go wrong and how do we set ourselves up for the best results? \nStiris’ QA Expert\, Kara Lee McWatters\, and President & CEO\, Shantal Feltham\, will discuss common findings from health authority inspections\, how to avoid pitfalls during an inspection\, day-to-day strategies you can implement\, challenges\, successes\, and real-life anecdotes to help you be inspection ready. Following the fireside chat\, there will be an open Q&A forum\, where you’ll have the opportunity to dig deeper into the information provided or ask your own questions. \nWant to guarantee your inspection question gets addressed? Submit ALL your questions via email at Auditing@StirisResearch.com or on Twitter @StirisResearch. \nStiris Research is a MassBIO member. MassBio Forums are networking and professional development that is planned for members by members to discuss industry hot topics\, tackle common challenges and share best practices. For those who cannot make it to Cambridge\, MassBio also webcasts all presentations live and archives the videos for on-demand replay in the Knowledge Base. See massbio.org for more information
URL:https://scienceinboston.com/event/fireside-chat-with-stiris-researchs-experts-on-health-authority-inspection-2/
LOCATION:MassBio\, 300 Technology Square 8th Fl\, Cambridge\, MA\, 02139\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191222T180000
DTEND;TZID=America/New_York:20191222T200000
DTSTAMP:20260716T173141
CREATED:20191209T231436Z
LAST-MODIFIED:20191209T231436Z
UID:7524-1577037600-1577044800@scienceinboston.com
SUMMARY:Going Beyond the Gut: The Future of Microbiome Therapeutics
DESCRIPTION:Overview\n\nThe microbiome market is one of the hottest areas for innovation in the life sciences space.  We are seeing an uptick in both research and venture capital dollars going into the microbiome industry—both in humans and plants.  As a result\, the global microbiome market is expected to grow from $235.8 million in 2018 to $521.23 million by 2022. \nPlease join us for a panel discussion led by some of Boston’s most innovative companies in the space to learn about the science behind the microbiome\, the utilization of emerging technologies\, and various perspectives on the future of the industry. \nConfirmed Speakers \nRyan Barrett\, VP\, Corporate Development & IP\,  Axial Biotherapeutics \nDr. Martha Herbert \, Assistant Professor of Neurology\, Harvard Medical School\, Pediatric Neurologist and Neuroscientist\,  Massachusetts General Hospital \nGeoff van Maltzahn\, Co-founder and Chief Innovation Officer\,  Indigo
URL:https://scienceinboston.com/event/going-beyond-the-gut-the-future-of-microbiome-therapeutics/
LOCATION:Broad Institute of MIT and Harvard\, 415 Main Street Auditorium\, Cambridge\, MA\, 02142\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191222T180000
DTEND;TZID=America/New_York:20191222T200000
DTSTAMP:20260716T173141
CREATED:20191209T231436Z
LAST-MODIFIED:20191209T231436Z
UID:27419-1577037600-1577044800@scienceinboston.com
SUMMARY:Going Beyond the Gut: The Future of Microbiome Therapeutics
DESCRIPTION:Overview\n\nThe microbiome market is one of the hottest areas for innovation in the life sciences space.  We are seeing an uptick in both research and venture capital dollars going into the microbiome industry—both in humans and plants.  As a result\, the global microbiome market is expected to grow from $235.8 million in 2018 to $521.23 million by 2022. \nPlease join us for a panel discussion led by some of Boston’s most innovative companies in the space to learn about the science behind the microbiome\, the utilization of emerging technologies\, and various perspectives on the future of the industry. \nConfirmed Speakers \nRyan Barrett\, VP\, Corporate Development & IP\,  Axial Biotherapeutics \nDr. Martha Herbert \, Assistant Professor of Neurology\, Harvard Medical School\, Pediatric Neurologist and Neuroscientist\,  Massachusetts General Hospital \nGeoff van Maltzahn\, Co-founder and Chief Innovation Officer\,  Indigo
URL:https://scienceinboston.com/event/going-beyond-the-gut-the-future-of-microbiome-therapeutics-3/
LOCATION:Broad Institute of MIT and Harvard\, 415 Main Street Auditorium\, Cambridge\, MA\, 02142\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200107T083000
DTEND;TZID=America/New_York:20200107T213000
DTSTAMP:20260716T173141
CREATED:20191209T224236Z
LAST-MODIFIED:20191209T224236Z
UID:7507-1578385800-1578432600@scienceinboston.com
SUMMARY:Harvard Medical School Master’s Degree Info Session
DESCRIPTION:Overview\n\nHarvard Medical School Postgraduate Medical Education Admissions team will host an online information session for three masters’ programs: Master in Clinical Service Operations\, Master of Healthcare Quality and Safety and Master of Medical Sciences in Clinical Investigation. \nHarvard Medical School faculty created these Master Degree Programs to address the needs of clinicians\, clinician-scientists and administrators in the areas of patient-oriented research\, and health care quality and safety. All three degrees combine innovative forms of pedagogy from leading Harvard faculty with an individual mentor experience in a Harvard affiliated laboratory or with a practical application at Harvard’s academic medical centers and community hospitals. \nAll degree programs prepare clinicians to assume leadership roles in their place of employment and to lead high profile projects.
URL:https://scienceinboston.com/event/harvard-medical-school-masters-degree-info-session/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200107T083000
DTEND;TZID=America/New_York:20200107T213000
DTSTAMP:20260716T173141
CREATED:20191209T224236Z
LAST-MODIFIED:20191209T224236Z
UID:27412-1578385800-1578432600@scienceinboston.com
SUMMARY:Harvard Medical School Master’s Degree Info Session
DESCRIPTION:Overview\n\nHarvard Medical School Postgraduate Medical Education Admissions team will host an online information session for three masters’ programs: Master in Clinical Service Operations\, Master of Healthcare Quality and Safety and Master of Medical Sciences in Clinical Investigation. \nHarvard Medical School faculty created these Master Degree Programs to address the needs of clinicians\, clinician-scientists and administrators in the areas of patient-oriented research\, and health care quality and safety. All three degrees combine innovative forms of pedagogy from leading Harvard faculty with an individual mentor experience in a Harvard affiliated laboratory or with a practical application at Harvard’s academic medical centers and community hospitals. \nAll degree programs prepare clinicians to assume leadership roles in their place of employment and to lead high profile projects.
URL:https://scienceinboston.com/event/harvard-medical-school-masters-degree-info-session-2/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200108T170000
DTEND;TZID=America/New_York:20200108T203000
DTSTAMP:20260716T173141
CREATED:20191209T224435Z
LAST-MODIFIED:20191209T224435Z
UID:7509-1578502800-1578515400@scienceinboston.com
SUMMARY:Post-Seed Venture Capital: What Is It? Is it Right for Me?
DESCRIPTION:Overview\n\nStartups: If you’re committed to your business vision\, then you MUST start planning for venture financing. \nEven if your startup is brand-new\, NOW is the time to map out your complete business growth path — all the way to venture financing. \nGet a crystal-clear picture of the process as we welcome three noted life science business financing experts to our Lowell center after work on Wednesday\, January 8. \nJoin us and: \n\nUnderstand how venture financing works today.\nLearn what to look for (and look OUT for) in a VC offer.\nLearn how to prepare your full business financing plan—from angel investors to VCs.\nFind out the preparations you need to make to advance to each stage of financing.\nGet expert answers to all your business financing questions.\nNetwork with VCs\, other investors\, and your entrepreneur peers.\nEnjoy complimentary snacks and beverages.\n\nPLUS\, practice and improve your pitch! \nCome with your pitch deck\, because you can enter your name to give your business presentation and get valuable feedback from our panel. \nAgenda: \n5:00 – Registration & Networking w/ food & drink \n5:30 – Fireside Chat with Bill Yelle\, Nancy Briefs\, and moderator Vinit Nijhawan. \n6:30 – Q&A and Networking \n  \nOnline tickets: $10.00 \nWalk-ins: $20.00 \n*This event will also include a 200k Challenge 2019 Info Session* \n*Free parking included*
URL:https://scienceinboston.com/event/post-seed-venture-capital-what-is-it-is-it-right-for-me/
LOCATION:M2D2\, 110 Canal Street\, 4th Floor\, Lowell\, MA\, 01854\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200108T170000
DTEND;TZID=America/New_York:20200108T203000
DTSTAMP:20260716T173141
CREATED:20191209T224435Z
LAST-MODIFIED:20191209T224435Z
UID:27413-1578502800-1578515400@scienceinboston.com
SUMMARY:Post-Seed Venture Capital: What Is It? Is it Right for Me?
DESCRIPTION:Overview\n\nStartups: If you’re committed to your business vision\, then you MUST start planning for venture financing. \nEven if your startup is brand-new\, NOW is the time to map out your complete business growth path — all the way to venture financing. \nGet a crystal-clear picture of the process as we welcome three noted life science business financing experts to our Lowell center after work on Wednesday\, January 8. \nJoin us and: \n\nUnderstand how venture financing works today.\nLearn what to look for (and look OUT for) in a VC offer.\nLearn how to prepare your full business financing plan—from angel investors to VCs.\nFind out the preparations you need to make to advance to each stage of financing.\nGet expert answers to all your business financing questions.\nNetwork with VCs\, other investors\, and your entrepreneur peers.\nEnjoy complimentary snacks and beverages.\n\nPLUS\, practice and improve your pitch! \nCome with your pitch deck\, because you can enter your name to give your business presentation and get valuable feedback from our panel. \nAgenda: \n5:00 – Registration & Networking w/ food & drink \n5:30 – Fireside Chat with Bill Yelle\, Nancy Briefs\, and moderator Vinit Nijhawan. \n6:30 – Q&A and Networking \n  \nOnline tickets: $10.00 \nWalk-ins: $20.00 \n*This event will also include a 200k Challenge 2019 Info Session* \n*Free parking included*
URL:https://scienceinboston.com/event/post-seed-venture-capital-what-is-it-is-it-right-for-me-2/
LOCATION:M2D2\, 110 Canal Street\, 4th Floor\, Lowell\, MA\, 01854\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200113T150000
DTEND;TZID=America/New_York:20200113T170000
DTSTAMP:20260716T173141
CREATED:20191209T224630Z
LAST-MODIFIED:20191209T224630Z
UID:7511-1578927600-1578934800@scienceinboston.com
SUMMARY:Beyond Bits to Bytes: Looking to the Future in Imaging and Data Science
DESCRIPTION:Overview\n\nThe role of data science in life science innovation is rapidly growing and evolving. If harnessed\, the information explosion has the potential to catalyze new discoveries and treatments in healthcare to benefit patients in need. During this time of digital transformation\, the potential exists to derive value from a wide variety of data sources\, including next generation sequencing\, mass spectrometry\, electronic health records\, images\, and consumer wearables. \nThe Massachusetts Life Sciences Center (MLSC) will convene various stakeholders to discuss how data is rapidly changing patient care. The gathering will feature voices from industry and academic research partners leading in this space. The event will feature a panel discussion covering a wide range of topics\, including requirements and standards for generating useful data\, patient privacy\, barriers to adoption\, and workforce training challenges. \nThe MLSC recently launched the second round of its Bits to Bytes Capital Call to provide funding for projects that will generate and analyze large datasets to answer pressing life science questions\, and train data scientists in the Commonwealth. The inaugural round of Bits to Bytes provided $6.7 million in capital funding to nine data-driven\, cross-sector projects focused on imaging\, cancer\, neuroscience\, drug discovery and clinical trial design.
URL:https://scienceinboston.com/event/beyond-bits-to-bytes-looking-to-the-future-in-imaging-and-data-science/
LOCATION:Broad Institute of MIT and Harvard\, 415 Main Street Auditorium\, Cambridge\, MA\, 02142\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200113T150000
DTEND;TZID=America/New_York:20200113T170000
DTSTAMP:20260716T173141
CREATED:20191209T224630Z
LAST-MODIFIED:20191209T224630Z
UID:27414-1578927600-1578934800@scienceinboston.com
SUMMARY:Beyond Bits to Bytes: Looking to the Future in Imaging and Data Science
DESCRIPTION:Overview\n\nThe role of data science in life science innovation is rapidly growing and evolving. If harnessed\, the information explosion has the potential to catalyze new discoveries and treatments in healthcare to benefit patients in need. During this time of digital transformation\, the potential exists to derive value from a wide variety of data sources\, including next generation sequencing\, mass spectrometry\, electronic health records\, images\, and consumer wearables. \nThe Massachusetts Life Sciences Center (MLSC) will convene various stakeholders to discuss how data is rapidly changing patient care. The gathering will feature voices from industry and academic research partners leading in this space. The event will feature a panel discussion covering a wide range of topics\, including requirements and standards for generating useful data\, patient privacy\, barriers to adoption\, and workforce training challenges. \nThe MLSC recently launched the second round of its Bits to Bytes Capital Call to provide funding for projects that will generate and analyze large datasets to answer pressing life science questions\, and train data scientists in the Commonwealth. The inaugural round of Bits to Bytes provided $6.7 million in capital funding to nine data-driven\, cross-sector projects focused on imaging\, cancer\, neuroscience\, drug discovery and clinical trial design.
URL:https://scienceinboston.com/event/beyond-bits-to-bytes-looking-to-the-future-in-imaging-and-data-science-2/
LOCATION:Broad Institute of MIT and Harvard\, 415 Main Street Auditorium\, Cambridge\, MA\, 02142\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200114T110000
DTEND;TZID=America/New_York:20200114T130000
DTSTAMP:20260716T173141
CREATED:20191209T225541Z
LAST-MODIFIED:20191209T225541Z
UID:7514-1578999600-1579006800@scienceinboston.com
SUMMARY:Exploring accessible R-groups using electrostatics and shape
DESCRIPTION:Overview\n\nSpark™ offers a rapid strategy for the identification of R-group replacements to explore new space. We will demonstrate in this hands-on workshop how Spark finds biologically equivalent replacements using electrostatic and shape character for key moieties in your molecule. Topics covered include R-group replacement\, grow a ligand into new space\, guided by existing ligands mapping a different region of the active site of your protein. \nHands-on: If you wish to follow along in this hands-on workshop then please bring a laptop (a download link to Spark will be provided before the event if needed). \nWho should attend: Medicinal\, synthetic and computational chemists with some experience of Spark.
URL:https://scienceinboston.com/event/exploring-accessible-r-groups-using-electrostatics-and-shape/
LOCATION:CIC\, Charles Room\, 14th Floor\, CIC\, 1 Broadway\, Cambridge\, MA\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200114T110000
DTEND;TZID=America/New_York:20200114T130000
DTSTAMP:20260716T173141
CREATED:20191209T225541Z
LAST-MODIFIED:20191209T225541Z
UID:27415-1578999600-1579006800@scienceinboston.com
SUMMARY:Exploring accessible R-groups using electrostatics and shape
DESCRIPTION:Overview\n\nSpark™ offers a rapid strategy for the identification of R-group replacements to explore new space. We will demonstrate in this hands-on workshop how Spark finds biologically equivalent replacements using electrostatic and shape character for key moieties in your molecule. Topics covered include R-group replacement\, grow a ligand into new space\, guided by existing ligands mapping a different region of the active site of your protein. \nHands-on: If you wish to follow along in this hands-on workshop then please bring a laptop (a download link to Spark will be provided before the event if needed). \nWho should attend: Medicinal\, synthetic and computational chemists with some experience of Spark.
URL:https://scienceinboston.com/event/exploring-accessible-r-groups-using-electrostatics-and-shape-2/
LOCATION:CIC\, Charles Room\, 14th Floor\, CIC\, 1 Broadway\, Cambridge\, MA\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200115T080000
DTEND;TZID=America/New_York:20200117T170000
DTSTAMP:20260716T173141
CREATED:20191209T225851Z
LAST-MODIFIED:20191209T225851Z
UID:7516-1579075200-1579280400@scienceinboston.com
SUMMARY:Recombinant Antibody and Biosimilars Course
DESCRIPTION:Overview\n\nRecombinant Antibody and Biosimilars course \nDates: January 15-17\, 2020 \nLocation: \nBiopharmaceutical Analysis Training Laboratory \nNortheastern University’s Innovation Campus \n147 S. Bedford Street\, Burlington\, MA 01803 \n  \nTOPICS COVERED \n\nGlycan analysis of immunoglobulins\nN- and C-terminal variants of antibody drugs\nStudy of disulfide connectivity and monitoring disulfide exchange\nMS based analysis of PK and metabolism of multivalent antibody drugs\nAnalysis of biosimilars in terms of variants and degradation products\n\n  \nLab course will be based on 1D gel and HPLC separation and LC/MS analysis of the following samples: \n\nIntact proteins\nReduced proteins e.g heavy and light chains\nTryptic digests which will contain glyco as well as other peptides\nGlycan mixtures released by glycosidase digestion of either the glycoprotein or enzyme digest\n\n  \nCost for this 2.5 training: \n$1900 per person\, Industry and Government \n$700 per person\, Academia \n  \nFor inquiries and to register\, email us at BATL@northeastern.edu \nFor more information about Northeastern’s Biopharmaceutical Analysis Training Laboratory\, visit our website: \nhttps://www.northeastern.edu/batl
URL:https://scienceinboston.com/event/recombinant-antibody-and-biosimilars-course/
LOCATION:Biopharmaceutical Analysis Training Laboratory\, Northeastern University’s Innovation Campus\, 147 S. Bedford Street\, Burlington\, MA\, 01803\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200115T080000
DTEND;TZID=America/New_York:20200117T170000
DTSTAMP:20260716T173141
CREATED:20191209T225851Z
LAST-MODIFIED:20191209T225851Z
UID:27416-1579075200-1579280400@scienceinboston.com
SUMMARY:Recombinant Antibody and Biosimilars Course
DESCRIPTION:Overview\n\nRecombinant Antibody and Biosimilars course \nDates: January 15-17\, 2020 \nLocation: \nBiopharmaceutical Analysis Training Laboratory \nNortheastern University’s Innovation Campus \n147 S. Bedford Street\, Burlington\, MA 01803 \n  \nTOPICS COVERED \n\nGlycan analysis of immunoglobulins\nN- and C-terminal variants of antibody drugs\nStudy of disulfide connectivity and monitoring disulfide exchange\nMS based analysis of PK and metabolism of multivalent antibody drugs\nAnalysis of biosimilars in terms of variants and degradation products\n\n  \nLab course will be based on 1D gel and HPLC separation and LC/MS analysis of the following samples: \n\nIntact proteins\nReduced proteins e.g heavy and light chains\nTryptic digests which will contain glyco as well as other peptides\nGlycan mixtures released by glycosidase digestion of either the glycoprotein or enzyme digest\n\n  \nCost for this 2.5 training: \n$1900 per person\, Industry and Government \n$700 per person\, Academia \n  \nFor inquiries and to register\, email us at BATL@northeastern.edu \nFor more information about Northeastern’s Biopharmaceutical Analysis Training Laboratory\, visit our website: \nhttps://www.northeastern.edu/batl
URL:https://scienceinboston.com/event/recombinant-antibody-and-biosimilars-course-2/
LOCATION:Biopharmaceutical Analysis Training Laboratory\, Northeastern University’s Innovation Campus\, 147 S. Bedford Street\, Burlington\, MA\, 01803\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200121T180000
DTEND;TZID=America/New_York:20200121T210000
DTSTAMP:20260716T173141
CREATED:20200102T192332Z
LAST-MODIFIED:20200102T192332Z
UID:7668-1579629600-1579640400@scienceinboston.com
SUMMARY:Seed and Angel Financing for Life Science Companies – Boston
DESCRIPTION:Life sciences entrepreneurs derive from a wide variety of geographic and educational backgrounds.  Young or old(er)\, most share a strong passion for translating their ideas and data into commercial products and services to benefit human health. While the work is rewarding\, it is a tremendously challenging endeavor\, from building the team to meeting regulatory requirements. Often\, the most daunting challenge is raising the financing needed to get started. The panelists for tonight’s ENET event have deep experience in launching life science startups\, from the perspectives of founder and investor\, and they are looking forward to sharing their insights with you. Please join us for an engaging discussion and stellar networking. \nAgenda: \n6:00-7:00 PM – Registration & Networking \n7:00-7:10 PM – ENET Chairman’s Announcements \n7:10-7:25 PM – eMinute PITCH – up to 3 startups give a 90-second elevator pitch \n7:25-8:15 PM – Expert speakers on the night’s topic \n8:15-8:30 PM – Q & A \n8:30-9:00 PM – Final networking\, including meeting speakers
URL:https://scienceinboston.com/event/seed-and-angel-financing-for-life-science-companies-boston/
LOCATION:Draper\, Hill Building\, One Hampshire St.\, Cambridge\, MA\, 02139\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200121T180000
DTEND;TZID=America/New_York:20200121T210000
DTSTAMP:20260716T173141
CREATED:20200102T192332Z
LAST-MODIFIED:20200102T192332Z
UID:27425-1579629600-1579640400@scienceinboston.com
SUMMARY:Seed and Angel Financing for Life Science Companies – Boston
DESCRIPTION:Life sciences entrepreneurs derive from a wide variety of geographic and educational backgrounds.  Young or old(er)\, most share a strong passion for translating their ideas and data into commercial products and services to benefit human health. While the work is rewarding\, it is a tremendously challenging endeavor\, from building the team to meeting regulatory requirements. Often\, the most daunting challenge is raising the financing needed to get started. The panelists for tonight’s ENET event have deep experience in launching life science startups\, from the perspectives of founder and investor\, and they are looking forward to sharing their insights with you. Please join us for an engaging discussion and stellar networking. \nAgenda: \n6:00-7:00 PM – Registration & Networking \n7:00-7:10 PM – ENET Chairman’s Announcements \n7:10-7:25 PM – eMinute PITCH – up to 3 startups give a 90-second elevator pitch \n7:25-8:15 PM – Expert speakers on the night’s topic \n8:15-8:30 PM – Q & A \n8:30-9:00 PM – Final networking\, including meeting speakers
URL:https://scienceinboston.com/event/seed-and-angel-financing-for-life-science-companies-boston-2/
LOCATION:Draper\, Hill Building\, One Hampshire St.\, Cambridge\, MA\, 02139\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200122T123000
DTEND;TZID=America/New_York:20200122T130000
DTSTAMP:20260716T173141
CREATED:20191209T230217Z
LAST-MODIFIED:20191209T230217Z
UID:7519-1579696200-1579698000@scienceinboston.com
SUMMARY:Synthetic Control Arms in Clinical Trials and Regulatory Applications
DESCRIPTION:Overview\n\nAs an increasing number of rare diseases and disease subsets become tractable to novel therapies\, there is growing pressure to increase the efficiency and effectiveness of clinical trials. One such approach is the use of real-world evidence\, such as synthetic control arms. Instead of recruiting patients who have been assigned to the control arm\, a synthetic control arm can repurpose historical clinical trial or real-world data to accurately match patients. This methodology has far-ranging applications in trial design\, replacement/augmentation of control groups and identifying differentiation in treatment effects across subpopulations. \nThis webinar will discuss the methodology and applicability of synthetic control arms\, especially those utilizing large clinical trial datasets\, in biopharma R&D. We will also discuss examples where synthetic controls have successfully been used in FDA applications\, and the emerging regulatory framework.
URL:https://scienceinboston.com/event/synthetic-control-arms-in-clinical-trials-and-regulatory-applications/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200122T123000
DTEND;TZID=America/New_York:20200122T130000
DTSTAMP:20260716T173141
CREATED:20191209T230217Z
LAST-MODIFIED:20191209T230217Z
UID:27417-1579696200-1579698000@scienceinboston.com
SUMMARY:Synthetic Control Arms in Clinical Trials and Regulatory Applications
DESCRIPTION:Overview\n\nAs an increasing number of rare diseases and disease subsets become tractable to novel therapies\, there is growing pressure to increase the efficiency and effectiveness of clinical trials. One such approach is the use of real-world evidence\, such as synthetic control arms. Instead of recruiting patients who have been assigned to the control arm\, a synthetic control arm can repurpose historical clinical trial or real-world data to accurately match patients. This methodology has far-ranging applications in trial design\, replacement/augmentation of control groups and identifying differentiation in treatment effects across subpopulations. \nThis webinar will discuss the methodology and applicability of synthetic control arms\, especially those utilizing large clinical trial datasets\, in biopharma R&D. We will also discuss examples where synthetic controls have successfully been used in FDA applications\, and the emerging regulatory framework.
URL:https://scienceinboston.com/event/synthetic-control-arms-in-clinical-trials-and-regulatory-applications-2/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200122T160000
DTEND;TZID=America/New_York:20200122T180000
DTSTAMP:20260716T173141
CREATED:20191209T231059Z
LAST-MODIFIED:20191209T231059Z
UID:7521-1579708800-1579716000@scienceinboston.com
SUMMARY:38th Annual JP Morgan Healthcare Conference Recap & 2020 Outlook
DESCRIPTION:The annual JP Morgan Healthcare Conference in San Francisco is one of the largest and most informative healthcare investment symposiums in the industry. It brings together global industry leaders\, emerging fast-growth companies\, innovative technology creators and members of the investment community. Each year hundreds of companies\, both public and private\, deliver presentations to over 4\,000 investors. In addition\, thousands in biotech descend upon San Francisco to network\, attend meetings and gain an inside view even if they can’t secure an official conference invite. If you can’t make it to the conference\, or if your role does not require you to attend the JP Morgan conference\, join us for a recap of it and hear ideas about the deals landscape for 2020 from a select group of conference insiders.
URL:https://scienceinboston.com/event/38th-annual-jp-morgan-healthcare-conference-recap-2020-outlook/
LOCATION:MassBio\, 300 Technology Square 8th Fl\, Cambridge\, MA\, 02139\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200122T160000
DTEND;TZID=America/New_York:20200122T180000
DTSTAMP:20260716T173141
CREATED:20191209T231059Z
LAST-MODIFIED:20191209T231059Z
UID:27418-1579708800-1579716000@scienceinboston.com
SUMMARY:38th Annual JP Morgan Healthcare Conference Recap & 2020 Outlook
DESCRIPTION:The annual JP Morgan Healthcare Conference in San Francisco is one of the largest and most informative healthcare investment symposiums in the industry. It brings together global industry leaders\, emerging fast-growth companies\, innovative technology creators and members of the investment community. Each year hundreds of companies\, both public and private\, deliver presentations to over 4\,000 investors. In addition\, thousands in biotech descend upon San Francisco to network\, attend meetings and gain an inside view even if they can’t secure an official conference invite. If you can’t make it to the conference\, or if your role does not require you to attend the JP Morgan conference\, join us for a recap of it and hear ideas about the deals landscape for 2020 from a select group of conference insiders.
URL:https://scienceinboston.com/event/38th-annual-jp-morgan-healthcare-conference-recap-2020-outlook-2/
LOCATION:MassBio\, 300 Technology Square 8th Fl\, Cambridge\, MA\, 02139\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200122T180000
DTEND;TZID=America/New_York:20200122T210000
DTSTAMP:20260716T173141
CREATED:20200102T190923Z
LAST-MODIFIED:20200102T190923Z
UID:7657-1579716000-1579726800@scienceinboston.com
SUMMARY:Going Beyond the Gut: The Future of Microbiome Therapeutics
DESCRIPTION:The microbiome market is one of the hottest areas for innovation in the life sciences space.  We are seeing an uptick in both research and venture capital dollars going into the microbiome industry—both in humans and plants.  As a result\, the global microbiome market is expected to grow from $235.8 million in 2018 to $521.23 million by 2022. \nPlease join us for a panel discussion led by some of Boston’s most innovative companies in the space to learn about the science behind the microbiome\, the utilization of emerging technologies\, and various perspectives on the future of the industry. \nConfirmed Speakers \nRyan Barrett\, VP\, Corporate Development & IP\,  Axial Biotherapeutics \nDr. Martha Herbert \, Assistant Professor of Neurology\, Harvard Medical School\, Pediatric Neurologist and Neuroscientist\,  Massachusetts General Hospital \nGeoff van Maltzahn\, Co-founder and Chief Innovation Officer\,  Indigo \n 
URL:https://scienceinboston.com/event/going-beyond-the-gut-the-future-of-microbiome-therapeutics-2/
LOCATION:Broad Institute of MIT and Harvard\, 415 Main Street Auditorium\, Cambridge\, MA\, 02142\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200122T180000
DTEND;TZID=America/New_York:20200122T210000
DTSTAMP:20260716T173141
CREATED:20200102T190923Z
LAST-MODIFIED:20200102T190923Z
UID:27421-1579716000-1579726800@scienceinboston.com
SUMMARY:Going Beyond the Gut: The Future of Microbiome Therapeutics
DESCRIPTION:The microbiome market is one of the hottest areas for innovation in the life sciences space.  We are seeing an uptick in both research and venture capital dollars going into the microbiome industry—both in humans and plants.  As a result\, the global microbiome market is expected to grow from $235.8 million in 2018 to $521.23 million by 2022. \nPlease join us for a panel discussion led by some of Boston’s most innovative companies in the space to learn about the science behind the microbiome\, the utilization of emerging technologies\, and various perspectives on the future of the industry. \nConfirmed Speakers \nRyan Barrett\, VP\, Corporate Development & IP\,  Axial Biotherapeutics \nDr. Martha Herbert \, Assistant Professor of Neurology\, Harvard Medical School\, Pediatric Neurologist and Neuroscientist\,  Massachusetts General Hospital \nGeoff van Maltzahn\, Co-founder and Chief Innovation Officer\,  Indigo \n 
URL:https://scienceinboston.com/event/going-beyond-the-gut-the-future-of-microbiome-therapeutics-2-2/
LOCATION:Broad Institute of MIT and Harvard\, 415 Main Street Auditorium\, Cambridge\, MA\, 02142\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200124T090000
DTEND;TZID=America/New_York:20200124T113000
DTSTAMP:20260716T173141
CREATED:20200102T191157Z
LAST-MODIFIED:20200102T191157Z
UID:7659-1579856400-1579865400@scienceinboston.com
SUMMARY:Don't Screw It Up - Choosing The Right Consultant: Important Considerations in Selecting the Right Regulatory and Quality Consultants for Your Projects
DESCRIPTION:Larger pharma company regulatory affairs and quality departments are constantly being asked to do more with no increase in resources. Smaller companies and foreign companies often do not have any or enough US based staff or staff with the appropriate expertise to meet their business goals. Thus the use of consultants to provide assistance is a significant and growing trend in both the pharmaceutical and medical device industries. \nBut how does one go about choosing a consultant group? Use a big CRO-type organization? Contact a single proprietor? Are there alternatives to consider in terms of therapeutic area\, geography\, on-site or remote work\, other potential add–on services that are offered\, etc.? This session will present the perspectives and learnings of a senior regulatory affairs executive with decades of successful experience and who has worked in both pharma and the consultancy industries. Similarly\, the second presenter will be a long-standing quality and compliance professional. \nIn choosing and utilizing regulatory and quality consultants for both tactical and strategic activities there are many attributes to consider. What information should you provide to allow a consultant to appropriately scope out\, determine timelines and resources\, and price a project? How should one compare proposals from different consultants? What should you verify with a consultant before signing the contract? An experienced consultancy executive will provide these insights and advise participants on what is needed to make the relationship work smoothly so that your objectives are fully realized. \nUse of regulatory affairs and quality consultants in the device/pharma industry is projected to continue to increase by 10% or more annually. Intermediate and senior level attendees will be able to apply the information shared during the presentations and Q&A session in their normal work activities as they consider adding consultants to complete business objectives. \nLearning Objectives: \n• Describe the key considerations in choosing an appropriate regulatory and quality consultant to meet business objectives. \n• Explain to a potential regulatory or quality consultant the essential aspects of a project that will allow an achievable timeline\, service delivery\, and budget to be presented for consideration. \nYour presenters will be Andrew S. Verderame\, Partner\, PharmaLex US Corporation and Gerardo Gomez\, Sr. Director Quality & Compliance\, PharmaLex US Corporation. \nA light breakfast will be served and there will be plenty of time for Q & A at the conclusion of the presentation.
URL:https://scienceinboston.com/event/dont-screw-it-up-choosing-the-right-consultant-important-considerations-in-selecting-the-right-regulatory-and-quality-consultants-for-your-projects/
LOCATION:MassBio\, 300 Technology Square 8th Fl\, Cambridge\, MA\, 02139\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200124T090000
DTEND;TZID=America/New_York:20200124T113000
DTSTAMP:20260716T173141
CREATED:20200102T191157Z
LAST-MODIFIED:20200102T191157Z
UID:27422-1579856400-1579865400@scienceinboston.com
SUMMARY:Don't Screw It Up - Choosing The Right Consultant: Important Considerations in Selecting the Right Regulatory and Quality Consultants for Your Projects
DESCRIPTION:Larger pharma company regulatory affairs and quality departments are constantly being asked to do more with no increase in resources. Smaller companies and foreign companies often do not have any or enough US based staff or staff with the appropriate expertise to meet their business goals. Thus the use of consultants to provide assistance is a significant and growing trend in both the pharmaceutical and medical device industries. \nBut how does one go about choosing a consultant group? Use a big CRO-type organization? Contact a single proprietor? Are there alternatives to consider in terms of therapeutic area\, geography\, on-site or remote work\, other potential add–on services that are offered\, etc.? This session will present the perspectives and learnings of a senior regulatory affairs executive with decades of successful experience and who has worked in both pharma and the consultancy industries. Similarly\, the second presenter will be a long-standing quality and compliance professional. \nIn choosing and utilizing regulatory and quality consultants for both tactical and strategic activities there are many attributes to consider. What information should you provide to allow a consultant to appropriately scope out\, determine timelines and resources\, and price a project? How should one compare proposals from different consultants? What should you verify with a consultant before signing the contract? An experienced consultancy executive will provide these insights and advise participants on what is needed to make the relationship work smoothly so that your objectives are fully realized. \nUse of regulatory affairs and quality consultants in the device/pharma industry is projected to continue to increase by 10% or more annually. Intermediate and senior level attendees will be able to apply the information shared during the presentations and Q&A session in their normal work activities as they consider adding consultants to complete business objectives. \nLearning Objectives: \n• Describe the key considerations in choosing an appropriate regulatory and quality consultant to meet business objectives. \n• Explain to a potential regulatory or quality consultant the essential aspects of a project that will allow an achievable timeline\, service delivery\, and budget to be presented for consideration. \nYour presenters will be Andrew S. Verderame\, Partner\, PharmaLex US Corporation and Gerardo Gomez\, Sr. Director Quality & Compliance\, PharmaLex US Corporation. \nA light breakfast will be served and there will be plenty of time for Q & A at the conclusion of the presentation.
URL:https://scienceinboston.com/event/dont-screw-it-up-choosing-the-right-consultant-important-considerations-in-selecting-the-right-regulatory-and-quality-consultants-for-your-projects-2/
LOCATION:MassBio\, 300 Technology Square 8th Fl\, Cambridge\, MA\, 02139\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200126T080000
DTEND;TZID=America/New_York:20200207T170000
DTSTAMP:20260716T173141
CREATED:20191209T231811Z
LAST-MODIFIED:20191209T231811Z
UID:7529-1580025600-1581094800@scienceinboston.com
SUMMARY:Program for Chairs of Clinical Services
DESCRIPTION:Overview\n\nChairs of major clinical departments traditionally have faced complex responsibilities because of their multiple tasks – patient care\, teaching\, research\, and administration. \nAs a result of the effects of health reform\, financial pressures\, and resource constraints\, many chairs are being asked by their institutions to become more extensively involved in institutional decision-making with regard to programs\, staffing\, operating and capital budgets\, and other issues\, such as the restructuring of the clinical enterprise. These responsibilities are in addition to their traditional concerns within their own departments. At the same time\, chairs have to consider to a greater degree the relationship between institutional priorities\, departmental decisions\, and collaboration with other services. These new tasks call for new leadership and managerial skills. \nThe Program for Chairs of Clinical Services brings together chairs of major clinical departments in teaching hospitals and health systems and an experienced interdisciplinary faculty for two weeks of intensive and systematic study of some of the critical leadership and management issues facing chairs\, their departments\, and teaching hospitals. \nCurriculum \nThe curriculum of the program is organized around the following interrelated courses taught by a faculty experienced in executive education for physicians and other key decision-makers in the health system: \n\nInstitutional Strategy\nHealth Policy\nFinancial Analysis and Control\nOperations Management\nOrganizational Issues\nLeadership Challenges\n\nA carefully integrated curriculum permits participants to examine fundamental managerial issues from the perspective of several disciplines. A new program initiative or downsizing proposal\, for example\, may raise managerial problems concerning departmental and institutional strategy; the application and utility of systems analysis and quantitative analytical methods; basic economic trends and legal constraints; financial analysis and control; and organizational behavior\, design\, and development. \nThe overriding purpose for learning concepts\, techniques\, and skills in any of the management disciplines in this program is to understand their managerial use and limitations. For example\, the course in financial analysis and control does not aim to develop expert accountants or to provide accounting skills\, per se. The purpose in learning to analyze the cost and financial implications of program decisions\, for instance\, is: (a) to better understand the fundamental methodological issues involved\, the driving factors behind any particular analysis\, the limits of such analysis\, and the need to blend this with clinical\, strategic\, and other non-financial judgements; and (b) to improve the ability of a participant both to manage staff and to interact more effectively with the fiscal affairs personnel in their hospital\, health system\, or medical school. \nTeaching Method \nThe principal method of instruction in the program is the case method\, a technique pioneered and refined at Harvard Business School. Most of the cases present actual problem situations familiar to chairs of clinical departments. Special case materials based on field studies of specific issues faced by service chairs have been and continue to be prepared by the faculty. \nThe case method confronts the participant with an actual management problem\, halted at a point where decisions must be made\, and forces the participant to choose a course of action. Participants go through a three-step study process. First\, participants study each case independently. Participants then meet in small discussion groups to test their individual analyses against those of their peers. Finally\, the entire class discusses the case\, with the professor as catalyst and guide. The professor points out considerations the class has overlooked; elicits from participants the lessons of experience; pursues each line of investigation to its conclusion; and finally\, summarizes the discussion and draws out the major lessons it has taught. \nAssigned readings and guest lecturers supplement and augment the use of cases. In addition\, an important part of the learning process occurs during the informal exchange of insights and experience among participants and faculty. \nProgram Organization \nClasses and discussion groups are scheduled six days a week. Preparation for classes averages six hours a day. Registration is scheduled for 3:00 – 4:00 pm on the opening Sunday of the program. The following Sunday is free except for cases to be prepared for Monday’s classes. The program concludes on the second Friday at 2:00 pm. Participants are required to free themselves of professional and family responsibilities for the period of the program so that full attention can be devoted to the educational experience.
URL:https://scienceinboston.com/event/program-for-chairs-of-clinical-services/
LOCATION:Harvard Longwood Campus\, Boston\, MA\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200126T080000
DTEND;TZID=America/New_York:20200207T170000
DTSTAMP:20260716T173141
CREATED:20191209T231811Z
LAST-MODIFIED:20191209T231811Z
UID:27420-1580025600-1581094800@scienceinboston.com
SUMMARY:Program for Chairs of Clinical Services
DESCRIPTION:Overview\n\nChairs of major clinical departments traditionally have faced complex responsibilities because of their multiple tasks – patient care\, teaching\, research\, and administration. \nAs a result of the effects of health reform\, financial pressures\, and resource constraints\, many chairs are being asked by their institutions to become more extensively involved in institutional decision-making with regard to programs\, staffing\, operating and capital budgets\, and other issues\, such as the restructuring of the clinical enterprise. These responsibilities are in addition to their traditional concerns within their own departments. At the same time\, chairs have to consider to a greater degree the relationship between institutional priorities\, departmental decisions\, and collaboration with other services. These new tasks call for new leadership and managerial skills. \nThe Program for Chairs of Clinical Services brings together chairs of major clinical departments in teaching hospitals and health systems and an experienced interdisciplinary faculty for two weeks of intensive and systematic study of some of the critical leadership and management issues facing chairs\, their departments\, and teaching hospitals. \nCurriculum \nThe curriculum of the program is organized around the following interrelated courses taught by a faculty experienced in executive education for physicians and other key decision-makers in the health system: \n\nInstitutional Strategy\nHealth Policy\nFinancial Analysis and Control\nOperations Management\nOrganizational Issues\nLeadership Challenges\n\nA carefully integrated curriculum permits participants to examine fundamental managerial issues from the perspective of several disciplines. A new program initiative or downsizing proposal\, for example\, may raise managerial problems concerning departmental and institutional strategy; the application and utility of systems analysis and quantitative analytical methods; basic economic trends and legal constraints; financial analysis and control; and organizational behavior\, design\, and development. \nThe overriding purpose for learning concepts\, techniques\, and skills in any of the management disciplines in this program is to understand their managerial use and limitations. For example\, the course in financial analysis and control does not aim to develop expert accountants or to provide accounting skills\, per se. The purpose in learning to analyze the cost and financial implications of program decisions\, for instance\, is: (a) to better understand the fundamental methodological issues involved\, the driving factors behind any particular analysis\, the limits of such analysis\, and the need to blend this with clinical\, strategic\, and other non-financial judgements; and (b) to improve the ability of a participant both to manage staff and to interact more effectively with the fiscal affairs personnel in their hospital\, health system\, or medical school. \nTeaching Method \nThe principal method of instruction in the program is the case method\, a technique pioneered and refined at Harvard Business School. Most of the cases present actual problem situations familiar to chairs of clinical departments. Special case materials based on field studies of specific issues faced by service chairs have been and continue to be prepared by the faculty. \nThe case method confronts the participant with an actual management problem\, halted at a point where decisions must be made\, and forces the participant to choose a course of action. Participants go through a three-step study process. First\, participants study each case independently. Participants then meet in small discussion groups to test their individual analyses against those of their peers. Finally\, the entire class discusses the case\, with the professor as catalyst and guide. The professor points out considerations the class has overlooked; elicits from participants the lessons of experience; pursues each line of investigation to its conclusion; and finally\, summarizes the discussion and draws out the major lessons it has taught. \nAssigned readings and guest lecturers supplement and augment the use of cases. In addition\, an important part of the learning process occurs during the informal exchange of insights and experience among participants and faculty. \nProgram Organization \nClasses and discussion groups are scheduled six days a week. Preparation for classes averages six hours a day. Registration is scheduled for 3:00 – 4:00 pm on the opening Sunday of the program. The following Sunday is free except for cases to be prepared for Monday’s classes. The program concludes on the second Friday at 2:00 pm. Participants are required to free themselves of professional and family responsibilities for the period of the program so that full attention can be devoted to the educational experience.
URL:https://scienceinboston.com/event/program-for-chairs-of-clinical-services-2/
LOCATION:Harvard Longwood Campus\, Boston\, MA\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200128T150000
DTEND;TZID=America/New_York:20200128T170000
DTSTAMP:20260716T173141
CREATED:20200102T191348Z
LAST-MODIFIED:20200102T191348Z
UID:7662-1580223600-1580230800@scienceinboston.com
SUMMARY:First Annual “Patient Safety in a Digital World” Symposium
DESCRIPTION:The Foundation for the Innovation and Development of Health Safety (FIDHS) is pleased to convene our 1st Annual International Patient Safety Symposium at Dana-Farber Cancer Institute in Boston. In an effort to move the needle on patient safety\, the symposium will convene thought leaders in digital health innovation\, hospital CEOs and their pharmacy leaders\, and patient safety executives from across the U.S. and Europe to address the latest digital strategies that ensure patient safety for hospitals\, insurers\, and pharma manufacturers. The symposium provides a global platform for medical professionals and innovators to collaborate on a vision of patient safety in a digital world\, providing insights and recommendations based on real world digital programs. \nMassBio President & CEO Robert K. Coughlin will deliver the Closing Keynote. Register to attend the event. \nAgenda Outline \n\n\n3:00 – 3:15 PM Welcome/Refreshments \n3:15 – 3:30 PM Opening Remarks \n3:30 – 4:15 PM Executive Panel Discussion: “Patient Safety\, International Considerations & Lessons Learned” \n4:15 – 4:45 PM Special Guest Speaker \n4:45 – 5:30 PM Executive Panel Discussion: “Safety in a Digital World\, Opportunities for Disruption” \n5:30 – 6:00 PM Closing Remarks \n6:00 – 8:00 PM Cocktail/Networking Reception
URL:https://scienceinboston.com/event/first-annual-patient-safety-in-a-digital-world-symposium/
LOCATION:Dana Farber Cancer Institute\, 450 Brookline Avenue\, Yawkey Center for Cancer Care\, Lavine Family Dining Pavilion\, 3rd Floor\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200128T150000
DTEND;TZID=America/New_York:20200128T170000
DTSTAMP:20260716T173141
CREATED:20200102T191348Z
LAST-MODIFIED:20200102T191348Z
UID:27423-1580223600-1580230800@scienceinboston.com
SUMMARY:First Annual “Patient Safety in a Digital World” Symposium
DESCRIPTION:The Foundation for the Innovation and Development of Health Safety (FIDHS) is pleased to convene our 1st Annual International Patient Safety Symposium at Dana-Farber Cancer Institute in Boston. In an effort to move the needle on patient safety\, the symposium will convene thought leaders in digital health innovation\, hospital CEOs and their pharmacy leaders\, and patient safety executives from across the U.S. and Europe to address the latest digital strategies that ensure patient safety for hospitals\, insurers\, and pharma manufacturers. The symposium provides a global platform for medical professionals and innovators to collaborate on a vision of patient safety in a digital world\, providing insights and recommendations based on real world digital programs. \nMassBio President & CEO Robert K. Coughlin will deliver the Closing Keynote. Register to attend the event. \nAgenda Outline \n\n\n3:00 – 3:15 PM Welcome/Refreshments \n3:15 – 3:30 PM Opening Remarks \n3:30 – 4:15 PM Executive Panel Discussion: “Patient Safety\, International Considerations & Lessons Learned” \n4:15 – 4:45 PM Special Guest Speaker \n4:45 – 5:30 PM Executive Panel Discussion: “Safety in a Digital World\, Opportunities for Disruption” \n5:30 – 6:00 PM Closing Remarks \n6:00 – 8:00 PM Cocktail/Networking Reception
URL:https://scienceinboston.com/event/first-annual-patient-safety-in-a-digital-world-symposium-2/
LOCATION:Dana Farber Cancer Institute\, 450 Brookline Avenue\, Yawkey Center for Cancer Care\, Lavine Family Dining Pavilion\, 3rd Floor\, Boston\, MA\, 02215\, United States
END:VEVENT
END:VCALENDAR